{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:57:36Z","timestamp":1790852256406,"version":"4.1.0"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdin.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:30:41Z","timestamp":1787495441000},"page":"121-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study"],"prefix":"10.1016","volume":"28","author":[{"given":"Joshua A.","family":"Kent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Santos","family":"Malave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-8531","authenticated-orcid":false,"given":"Yoni","family":"Sacknovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdin.2026.08.003_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jaad.2020.10.074","article-title":"Utilization and cost of topical calcineurin inhibitors in the Medicare population: 2013 to 2017","volume":"85","author":"Ugwu","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.jdin.2026.08.003_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"10.1016\/j.jdin.2026.08.003_bib4","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy","volume":"44","author":"Hanifin","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2026.08.003_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:15:23Z","timestamp":1790849723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328726001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":4,"alternative-id":["S2666328726001483"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2026.08.003","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}